Moderna 报告第四季度财务业绩。 Moderna reports fourth quarter finacial results.
Moderna 在 2023 年第四季度和财年财务业绩中公布了令人惊讶的利润，第四季度营收为 28 亿美元，净利润为 2.17 亿美元。 Moderna reported a surprise profit in its Q4 and FY 2023 financial results, posting fourth-quarter revenues of $2.8bn and a net income of $217m. 全年收入达到 68 亿美元，净亏损 47 亿美元，主要归因于非现金费用。 Full-year revenues reached $6.8bn, with a net loss of $4.7bn largely due to non-cash charges. 尽管疫苗销售额较低，Moderna 仍重申其 2024 年产品销售额约为 40 亿美元的预测，并预计其用于老年人的研究性 RSV 疫苗将于 2024 年上半年开始获得监管部门批准，今年其后期管道将取得更多关键里程碑。 Despite lower vaccine sales, Moderna reaffirmed its 2024 product sales forecast of approximately $4bn and expects regulatory approvals for its investigational RSV vaccine for older adults beginning in the first half of 2024, with additional key milestones from its late-stage pipeline this year.